http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-20080594-L
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8092b9ec2a531edd1f796a5b8cb01e4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2008-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91b47bc9daacced7aaf4008484a2a30b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c50b374bdf295cbe81908f1f55315a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fd8131a8485a1514d7b1f7206957a38 |
| publicationDate | 2008-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NO-20080594-L |
| titleOfInvention | Heteroberl-substituted diazatric cycloalkanes, processes for their preparation and use |
| abstract | The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatric cycloalkanes of formula (I) with the definitions set forth in the specification, pharmaceutical compositions comprising the compounds, methods of preparing the compounds and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the a7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the a7 nAChR subtype. Diazatric cycloalkanes typically consist of a 1-azabicyclooctane fused to a pyrrolidine ring. Substituent heteroaryl groups are 5- or 6-membered heteroaromatic ring groups, such as 3-pyridinyl and 5-pyrimidinyl groups, which are directly linked to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine group is substituted by an arylcarbonyl (amide type derivative) or arylaminocarbonyl (N-arylcarbamoyl) (urea type derivative) group. The compounds are advantageous for therapeutic applications requiring selective interaction with certain nAChR subtypes. Ie the compounds modulate the activity of certain nAChR subtypes, especially the a7 nAChR subtype and have no appreciable activity against muscarinic receptors. Radioactively labeled versions of the compounds can be used for diagnostic methods. (IN) |
| priorityDate | 2005-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.